Cargando…

Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers

Ovarian cancer is one of the most lethal gynecological malignancies worldwide, and chemoresistance is a critical obstacle in the clinical management of the disease. Recent studies have suggested that exploiting cancer cell metabolism by applying AMP-activated protein kinase (AMPK)-activating agents...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yung, Mingo M. H., Siu, Michelle K. Y., Ngan, Hextan Y. S., Chan, David W., Chan, Karen K. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224484/ https://www.ncbi.nlm.nih.gov/pubmed/35743298 http://dx.doi.org/10.3390/ijms23126857

Ejemplares similares

New Insights into Ferroptosis Initiating Therapies (FIT) by Targeting the Rewired Lipid Metabolism in Ovarian Cancer Peritoneal Metastases
por: Zhan, Shijie, et al.
Publicado: (2022)

Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade
por: Yung, Mingo M. H., et al.
Publicado: (2015)

Molecular Biomarkers for the Early Detection of Ovarian Cancer
por: Zhang, Ruiqian, et al.
Publicado: (2022)

A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer
por: Wang, Jing-Jing, et al.
Publicado: (2021)

The Stress-Inducible BCL2A1 Is Required for Ovarian Cancer Metastatic Progression in the Peritoneal Microenvironment
por: Liang, Rui, et al.
Publicado: (2021)

Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets
por: He, Jiangnan, et al.
Publicado: (2021)

Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade
por: Yung, Mingo Ming Ho, et al.
Publicado: (2013)

Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications
por: Li, Cuilan, et al.
Publicado: (2012)

The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression
por: Wang, Huogang, et al.
Publicado: (2021)

AMPK Activators Suppress Cervical Cancer Cell Growth through Inhibition of DVL3 Mediated Wnt/β-Catenin Signaling Activity
por: Kwan, H. T., et al.
Publicado: (2013)

Ascensión Tun : novela
por: Molina, Silvia, 1946-
Publicado: (1981)

SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells
por: Xuan, Yang, et al.
Publicado: (2022)

Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers
por: Chan, David W., et al.
Publicado: (2021)

Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
por: Chan, David W., et al.
Publicado: (2012)

Correction to: Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers
por: Chan, David W., et al.
Publicado: (2021)

Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells
por: Chen, Rain R., et al.
Publicado: (2019)

Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer
por: Li, Cuilan, et al.
Publicado: (2014)

Epigenetic Silencing of miR-33b Promotes Peritoneal Metastases of Ovarian Cancer by Modulating the TAK1/FASN/CPT1A/NF-κB Axis
por: Wang, Xueyu, et al.
Publicado: (2021)

Tumour Suppressive Function and Modulation of Programmed Cell Death 4 (PDCD4) in Ovarian Cancer
por: Wei, Na, et al.
Publicado: (2012)

Correction: Reduced expression of AMPK-ß1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer
por: Li, Cuilan, et al.
Publicado: (2014)

A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
por: Ngu, Siew-Fei, et al.
Publicado: (2022)

Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis
por: Mo, Yulan, et al.
Publicado: (2023)

Was tun bei (therapieresistenter) Skabies
por: Schaller, Martin
Publicado: (2022)

Schnupfen bei Kindern – was tun?
Publicado: (2023)

Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer
por: Chan, Karen K. L., et al.
Publicado: (2018)

Wo Menschen und Teilchen aufeinanderstossen: CERN : warum wir das tun, was wir tun
por: Krause, Michael
Publicado: (2015)

PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF-κB Signaling Pathway in Ovarian Cancer
por: Jiang, Yu-xin, et al.
Publicado: (2022)

Viel zu tun im Gesundheitswesen
por: Weih, Markus
Publicado: (2020)

Was tun mit Atemwegspatienten in Corona-Zeiten?
por: Barczok, Michael
Publicado: (2021)

MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis
por: Mak, Celia S. L., et al.
Publicado: (2017)

Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis
por: Chan, Karen K. L., et al.
Publicado: (2017)

A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer
por: Helali, Aya El, et al.
Publicado: (2022)

Increased Expression of PITX2 Transcription Factor Contributes to Ovarian Cancer Progression
por: Fung, Frederic K. C., et al.
Publicado: (2012)

Lungenkrebsscreening: Was tun mit Rundherden unklarer Dignität?
por: Meißner, Thomas
Publicado: (2021)

Praxis und Warteliste quellen über - was tun?
por: Carl, Gunther
Publicado: (2021)

PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via α5β1 integrin and JNK/IL-8 signaling
por: Siu, Michelle K. Y., et al.
Publicado: (2020)

Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients
por: Kwong, Ava, et al.
Publicado: (2021)

Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome
por: Siu, Michelle K. Y., et al.
Publicado: (2012)

Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades
por: Siu, Michelle K. Y., et al.
Publicado: (2019)

Patient-Initiated Follow-Up in Ovarian Cancer
por: Luk, Hiu Mei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ognajr0s9hv1nseiu79psjba04